Holger Crafoord and Nils Alwall in front of the first Gambro kidney (Photo belongs to Lund University, Sweden).
Our heritage goes back to professor Nils Alwall, nephrology chair at Lund University, and one of the founding fathers of dialysis who inspired the creation of Gambro Inc, one of the major dialysis equipment manufacturers for many decades.
Our origin dates to the founding of Gambro Healthcare division and the opening of the first dialysis clinic in Sweden, Lund, in 1991.
From Sweden, Gambro healthcare clinics expanded to the rest of the world, and in 2007 operated 153 clinics in 11 countries, treating more than 12 000 renal patients.
In 2007, Gambro Healthcare was acquired by Bridgepoint with the vision to help healthcare systems across the world to provide universal access to world-class renal care and deliver life enhancing renal care to patients globally.
Together with the new vision, the name Diaverum was adopted and launched worldwide.
During the following years, Diaverum became synonymous with quality, clinical governance and culture of true care, while during the same period it has expanded substantially and today operates more than 400 clinics in 22 countries serving more than 39 500 patients globally.
Important milestones in our history
Below are important milestones and events of Diaverum’s history of growth.
Gambro opens its first dialysis clinic in Sweden, Lund.
Bridgepoint acquires Gambro Healthcare from EQT and Investor AB, subsequently changing company name to Diaverum. The business is at the time the second largest corporate provider of dialysis care services in Europe with 155 clinics in 14 countries serving 12,000 patients and with ancillary businesses in South America and Australia.
Diaverum enters Germany with three acquisitions of seven clinics in Kleve, Erkelenz and Potsdam.
Diaverum enters Saudi Arabia in a joint venture with Nazer Group and initially establishes one greenfield clinic in Dammam. Diaverum enters Chile with the acquisition of four clinics. Diaverum enters Romania and adds nine clinics across the country.
Diaverum Germany expands, adding four new clinics in Hamburg, one of them being one of the largest dialysis clinics in Europe.
Diaverum wins 50% of outsourced dialysis services contract with Ministry of Health Saudi Arabia to care for more than 5,000 patients. Diaverum enters Russia by acquiring ten clinics of Unona, mainly located in the Sverdlovsk region.
Diaverum enters the Asian market through its acquisition of Nefros Asia in Kazakhstan with nine kidney centres across the country.
Diaverum acquires International Healthcare Systems (IHS) in Romania and adds 15 new clinics to the network.
Diaverum opens state of the art transplant center d.INSTITUTE ITAC for complex transplants in Argentina. Diaverum enters Brazil and North Macedonia.
Diaverum enters Albania, and enters Morocco through a partnership with Centre d’Hémodialyse de Marrakech, expanding Diaverum’s presence to 22 countries worldwide. Diaverum strengthens its presence in the Middle East with renewal of its five-year dialysis contract in Saudi Arabia. Diaverum serves more than 39,000 patients in more than 400 clinics across the globe excluding the US.
In January 2020 and almost two months before the WHO declared the pandemic, Diaverum issues its first policies to contain the SARS-CoV-2 contagion in its clinics. Shortly after, in February, its COVID-19 Contingency Plan was made available publicly on its website. Continuing to expand its global presence, Diaverum enters Singapore and Malaysia with the acquisition of Advance Renal Care Asia. In Brazil, it acquires the CTN clinic in São Paulo.
The organisation continues to expand its global presence, with new, state-of-the-art headquarters in Sweden and with clinics opening in Brazil, Chile, China, Morocco, Portugal & the UK. In July, Diaverum becomes a member of the Ethical Principals in Healthcare (EPiHC) and shortly after, is accredited by the Joint Commission International (JCI) for its ambulatory care network in Saudi Arabia. In October, the organisation launches a breakthrough VA thrombosis prediction AI model. COVID-19 vaccination continues to be a priority for Diaverum – by year-end, it records an impressive 86% of patients and 94% of staff receiving their first dose, with 52% of patients having already had their booster shot.